Sanofi Moves Forward with Sale of Doliprane Unit to American Fund CD&R

Despite employee protests and a competing bid, Sanofi remains committed to selling 50% of its Opella unit to CD&R, emphasizing strategic growth and maintaining French operations.

Sanofi is finalizing negotiations to sell 50% of its Opella unit, which includes the popular Doliprane brand, to American investment fund Clayton, Dubilier & Rice (CD&R).
The decision has sparked protests from employees at Sanofi's Compiègne and Lisieux sites, who are concerned about potential job losses and lack of transparency.
Sanofi's president for France, Audrey Duval, assured that the company will retain a 50% stake in Opella, allowing it to maintain strategic control and veto power.
The French government has expressed concerns over national health sovereignty and is seeking guarantees on employment and production continuity.
A late bid from French fund PAI was rejected by Sanofi, which is focused on its strategy to pivot towards innovation and growth.